Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jan;27(1):332-334.
doi: 10.3201/eid2701.203766. Epub 2020 Nov 23.

Novel 6-Month Treatment for Drug-Resistant Tuberculosis, United States

Connie A Haley, Patricia Macias, Supriya Jasuja, Betsy A Jones, Marie-Claire Rowlinson, Roshni Jaimon, Pennelyn Onderko, Elaine Darnall, Maria E Gomez, Charles Peloquin, David Ashkin, Neela D Goswami

Novel 6-Month Treatment for Drug-Resistant Tuberculosis, United States

Connie A Haley et al. Emerg Infect Dis. 2021 Jan.

Abstract

The US Food and Drug Administration approved a 6-month regimen of pretomanid, bedaquiline, and linezolid for extensively drug-resistant or multidrug-intolerant tuberculosis after a trial in South Africa demonstrated 90% effectiveness 6 months posttreatment. We report on a patient who completed the regimen using a lower linezolid dose.

Keywords: BPaL; Nix-TB; United States; antimicrobial resistance; bacteria; bedaquiline; drug monitoring; linezolid; pretomanid; tuberculosis and other mycobacteria.

PubMed Disclaimer

References

    1. Conradie F, Diacon AH, Ngubane N, Howell P, Everitt D, Crook AM, et al.; Nix-TB Trial Team. Treatment of highly drug-resistant pulmonary tuberculosis. N Engl J Med. 2020;382:893–902. 10.1056/NEJMoa1901814 - DOI - PMC - PubMed
    1. Keam SJ. Pretomanid: first approval. Drugs. 2019;79:1797–803. 10.1007/s40265-019-01207-9 - DOI - PubMed
    1. Lee M, Lee J, Carroll MW, Choi H, Min S, Song T, et al. Linezolid for treatment of chronic extensively drug-resistant tuberculosis. N Engl J Med. 2012;367:1508–18. 10.1056/NEJMoa1201964 - DOI - PMC - PubMed
    1. Brown AN, Drusano GL, Adams JR, Rodriquez JL, Jambunathan K, Baluya DL, et al. Preclinical evaluations to identify optimal linezolid regimens for tuberculosis therapy. MBio. 2015;6:e01741–15. 10.1128/mBio.01741-15 - DOI - PMC - PubMed
    1. Nahid P, Mase SR, Migliori GB, Sotgiu G, Bothamley GH, Brozek JL, et al. Treatment of drug-resistant tuberculosis. An official ATS/CDC/ERS/IDSA clinical practice guideline. Am J Respir Crit Care Med. 2019;200:e93–142. 10.1164/rccm.201909-1874ST - DOI - PMC - PubMed

MeSH terms

LinkOut - more resources